Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2.
BA.1
BA.1.1
BA.2
COVID-19
Omicron
SARS-CoV-2
mRNA vaccine
neutralizing antibody
Journal
Cell host & microbe
ISSN: 1934-6069
Titre abrégé: Cell Host Microbe
Pays: United States
ID NLM: 101302316
Informations de publication
Date de publication:
10 08 2022
10 08 2022
Historique:
received:
29
03
2022
revised:
07
04
2022
accepted:
20
04
2022
pubmed:
9
5
2022
medline:
16
8
2022
entrez:
8
5
2022
Statut:
ppublish
Résumé
Recent reports of SARS-CoV-2 Omicron variant sub-lineages, BA.1, BA.1.1, and BA.2, have reignited concern over potential escape from vaccine- and infection-induced immunity. We examine the sensitivity of these sub-lineages and other major variants to neutralizing antibodies from mRNA-vaccinated and boosted individuals, as well as recovered COVID-19 patients, including those infected with Omicron. We find that all Omicron sub-lineages, especially BA.1 and BA.1.1, exhibit substantial immune escape that is largely overcome by mRNA vaccine booster doses. While Omicron BA.1.1 escapes almost completely from neutralization by early-pandemic COVID-19 patient sera and to a lesser extent from sera of Delta-infected patients, BA.1.1 is sensitive to Omicron-infected patient sera. Critically, all Omicron sub-lineages, including BA.2, are comparably neutralized by Omicron patient sera. These results highlight the importance of booster vaccine doses for protection against all Omicron variants and provide insight into the immunity from natural infection against Omicron sub-lineages.
Identifiants
pubmed: 35526534
pii: S1931-3128(22)00220-7
doi: 10.1016/j.chom.2022.04.014
pmc: PMC9035359
mid: NIHMS1801957
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Spike Glycoprotein, Coronavirus
0
Vaccines, Synthetic
0
mRNA Vaccines
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1093-1102.e3Subventions
Organisme : NCI NIH HHS
ID : U54 CA260582
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD095881
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002733
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR002734
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI150473
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL096376
Pays : United States
Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests The authors declare no competing interests.
Références
Nature. 2021 Apr;592(7852):116-121
pubmed: 33106671
Trends Immunol. 2022 Mar;43(3):170-172
pubmed: 35125310
Nature. 2022 Feb;602(7898):671-675
pubmed: 35016199
J Med Virol. 2022 May;94(5):1777-1779
pubmed: 34964502
Biomed Pharmacother. 2020 Oct;130:110629
pubmed: 33406577
mBio. 2021 Oct 26;12(5):e0251021
pubmed: 34607452
Science. 2022 May 6;376(6593):eabn4947
pubmed: 35289632
N Engl J Med. 2021 May 13;384(19):1866-1868
pubmed: 33761203
Sci Rep. 2022 Nov 18;12(1):19858
pubmed: 36400804
Science. 2022 Mar 4;375(6584):1048-1053
pubmed: 35133176
Metab Eng. 2008 May-Jul;10(3-4):187-200
pubmed: 18555198
MMWR Morb Mortal Wkly Rep. 2021 Sep 17;70(37):1284-1290
pubmed: 34529637
Nature. 2022 Mar;603(7902):687-692
pubmed: 35062015
Nat Commun. 2022 Mar 3;13(1):1214
pubmed: 35241675
Nature. 2021 Nov;599(7883):114-119
pubmed: 34488225
Nature. 2022 Mar;603(7903):919-925
pubmed: 35090164
Cell Res. 2022 May;32(5):495-497
pubmed: 35210607
Immunity. 2021 Aug 10;54(8):1853-1868.e7
pubmed: 34331873
Emerg Microbes Infect. 2022 Dec;11(1):477-481
pubmed: 35034583
Cell. 2022 Feb 3;185(3):447-456.e11
pubmed: 35026151
Lancet. 2022 Feb 12;399(10325):625-626
pubmed: 35063123
Cell Rep. 2022 Mar 1;38(9):110428
pubmed: 35172173
Cell Biosci. 2021 Nov 21;11(1):197
pubmed: 34802457
J Med Virol. 2022 Apr;94(4):1728-1733
pubmed: 34897752
Cell Mol Immunol. 2021 Feb;18(2):318-327
pubmed: 33408342
Nat Med. 2022 Mar;28(3):481-485
pubmed: 35051990
Nat Med. 2021 Jul;27(7):1131-1133
pubmed: 34045737
JCI Insight. 2020 Nov 19;5(22):
pubmed: 33035201
N Engl J Med. 2022 Feb 10;386(6):599-601
pubmed: 35030645
Nat Commun. 2022 Feb 9;13(1):852
pubmed: 35140233
Cell Host Microbe. 2022 Apr 13;30(4):485-488.e3
pubmed: 35245438
mBio. 2022 Aug 30;13(4):e0084022
pubmed: 35735743
Cell. 2021 Apr 29;184(9):2348-2361.e6
pubmed: 33730597
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
N Engl J Med. 2022 Apr 21;386(16):1579-1580
pubmed: 35294809
Nature. 2022 Mar;603(7901):493-496
pubmed: 35102312
Emerg Microbes Infect. 2022 Dec;11(1):1-5
pubmed: 34890524
Signal Transduct Target Ther. 2020 Sep 22;5(1):212
pubmed: 32963228
Cell. 2021 May 13;184(10):2587-2594.e7
pubmed: 33861950
Cell Host Microbe. 2022 Mar 9;30(3):373-387.e7
pubmed: 35150638
JCI Insight. 2022 Oct 10;7(19):
pubmed: 36214224
Cell. 2020 Oct 29;183(3):739-751.e8
pubmed: 32991842
Lancet. 2021 Dec 11;398(10317):2126-2128
pubmed: 34871545
PLoS Pathog. 2010 Feb 26;6(2):e1000788
pubmed: 20195464
Med. 2022 Apr 8;3(4):262-268.e4
pubmed: 35313451
Sci Transl Med. 2022 Mar 23;14(637):eabn8057
pubmed: 35166573